Icon	Function
💬	A pop-up explanation appears when you mouse-over the text beside this icon. Also, an explanation window appears when you click this icon.
	The links beside this icon are links to external sites.
	Clicking this icon sorts the table by the item with this icon (Numerical or alphabetical order). Each click toggles between ascending and descending order.
	A text longer than 100 characters is fully displayed or collapsed.
	The contents of the displayed table are downloaded as a file named "table.csv".

DR info

Clinical trials : 12 / Drugs : 5 - (DrugBank : 1) / Drug target gene : 1 - Drug target pathways : 43

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)

ACZ885
   Novartis Farma SpA
      2014   Phase 3   EUCTR2013-004291-35-IT   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2014   Phase 3   EUCTR2013-004291-35-ES   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-004291-35-NL   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004291-35-IE   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004291-35-HU   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004291-35-GR   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004291-35-BE   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
   Novartis pharma AG
      -   Phase 3   EUCTR2017-001678-40-Outside-EU/EEA   Japan
ACZ885, 150MG/1.0ML
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-004291-35-DE   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
Canakinumab
   Novartis Farma SpA
      2014   Phase 3   EUCTR2013-004291-35-IT   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2014   Phase 3   EUCTR2013-004291-35-ES   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-004291-35-NL   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004291-35-IE   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004291-35-HU   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004291-35-GR   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004291-35-DE   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004291-35-BE   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
   Novartis Pharmaceuticals
      2011   Phase 2   NCT01303380   Spain
   Novartis pharma AG
      -   Phase 3   EUCTR2017-001678-40-Outside-EU/EEA   Japan
Ilaris
   Novartis Farma SpA
      2014   Phase 3   EUCTR2013-004291-35-IT   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2014   Phase 3   EUCTR2013-004291-35-ES   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-004291-35-NL   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004291-35-DE   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
   Novartis Pharmaceuticals
      2025   -   NCT06838143   -
   Novartis pharma AG
      -   Phase 3   EUCTR2017-001678-40-Outside-EU/EEA   Japan
ITF2357
   Radboud University
      2006   Phase 2   NCT00442182   Netherlands